Probelte Pharma S.L.U.
5
2
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.5% vs industry average
20%
1 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp.
Role: lead
Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM
Role: lead
Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With House Dust Mites
Role: collaborator
Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Alternaria Alternata
Role: lead
Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Cat Dander
Role: lead
All 5 trials loaded